Nkarta Announces Leadership Changes
05 oct. 2020 16h02 HE
|
Nkarta, Inc.
Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business OfficerAlicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE...
Nkarta Announces October 2020 Investor Conference Schedule
29 sept. 2020 08h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces September 2020 Virtual Investor Conference Schedule
08 sept. 2020 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Reports Second Quarter 2020 Financial Results
20 août 2020 16h02 HE
|
Nkarta, Inc.
Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021Completed construction of cGMP clinical manufacturing facilityCompleted...
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
14 juil. 2020 16h15 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces Pricing of Initial Public Offering
10 juil. 2020 00h44 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II
22 juin 2020 09h52 HE
|
Nkarta
Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing Combination of engineered natural killer cells and engineered T cells demonstrated potential...
Nkarta Therapeutics Appoints Two New Independent Directors
27 avr. 2020 08h30 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference
09 janv. 2020 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development
09 déc. 2019 08h00 HE
|
Nkarta
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...